A similar decrease in PD-L2 expression was observed on activated B cells in patients with CLL (0.3624 ± 0.2514) compared to the control group (1.137 ± 0.9655; p = 0.0186). This evidence concerns the gene PDCD1LG2 and B-cell chronic lymphocytic leukemia.